Chlamydia - Market Insights, Epidemiology, and Market Forecast - 2032

The ‘Chlamydia - Market Insights, Epidemiology, and Market Forecast - 2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of chlamydia in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Chlamydia market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Chlamydia market Size from 2019 to 2032, segmented by seven major markets. The report also covers the current Chlamydia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Chlamydia: Disease Understanding and Treatment Algorithm

Chlamydia Overview

Chlamydial infection, caused by Chlamydia trachomatis, is the most common bacterial sexually transmitted infection (STI). Age is a strong predictor of risk for chlamydial infections, with the highest infection rates in women occurring during ages 15-24 years. As most individuals with the infection are asymptomatic, it is often left untreated, increasing the risk of transmission and serious health consequences in both sexes. If symptoms occur, they usually appear two to six weeks after infection. Symptoms can include vaginal pain and bleeding, painful urination, and an abnormal discharge from the vagina, urethra, or rectum.

Untreated infection can result in serious complications such as pelvic inflammatory disease, infertility, ectopic pregnancy in women, and epididymitis and orchitis in men. Maternal infection is associated with serious adverse outcomes in neonates, such as preterm birth, low birth weight, conjunctivitis, nasopharyngeal infection, and pneumonia. Screening for chlamydia is implemented in several countries and regions, including the US and the UK, to reduce the risks. Screening is recommended in all women younger than 25 years, in all pregnant women, and in women who are at increased risk of infection.

The Aptima Combo 2 Assay and the Xpert CT/NG were the first tests cleared for extragenital diagnostic testing to detect the presence of the bacteria Chlamydia trachomatis via the throat and rectum. These tests were previously only cleared for testing urine, vaginal and endocervical samples. The availability of these two tests helped fill an unmet public health need by allowing for more screening. Recently, US FDA approved using the Binx Health IO CT/NG Assay at point-of-care settings to help with more quick and appropriate treatment of chlamydia. Access to faster diagnostic results and proper treatments will make significant strides in combatting Chlamydia infections.

Treating C. trachomatis prevents adverse reproductive health complications and continued sexual transmission. Furthermore, treating the sex partners prevent reinfection and infection of other partners. Also, treating pregnant women usually prevents C. trachomatis in neonates during birth. For the treatment of chlamydia infection, the Centers for Disease Control and Prevention (CDC) recommends 100 mg of doxycycline twice daily for 7 days. Alternate regimens include oral administration of either 1 g of azithromycin in a single dose of Levofloxacin 500 mg orally once daily for 7 days.

While antibiotics have successfully treated most uncomplicated C. trachomatis urogenital infections, treatment does not generally resolve persistent infections or prevent autoimmunity. Repeat and persistent infections are common among at-risk adolescent and young adult populations. Even with appropriate detection, there is increasing evidence for antibiotic resistance to the common drugs used to treat C. trachomatis.

Chlamydia Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the Chlamydia market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The Chlamydia Market Report gives a thorough understanding of chlamydia by including details of disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for Chlamydia in the US, Europe, and Japan.

Chlamydia Epidemiology

The Chlamydia epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed incident patient pool, trends, and assumptions.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Chlamydia epidemiology segmented as the diagnosed incident cases of chlamydia, gender-specific cases of chlamydia, symptom-specific cases of Chlamydia and age-specific cases of Chlamydia. The report includes the diagnosed incident scenario of Chlamydia symptoms in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise Chlamydia Epidemiology

The epidemiology segment also provides the Chlamydia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The diagnosed incident Chlamydia population in the 7MM countries was estimated to be 3,453,387 cases in 2021.

Chlamydia Drug Chapters

The drug chapter segment of the Chlamydia report encloses the detailed analysis of Chlamydia marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) pipeline drugs. It also helps to understand the Chlamydia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Recently, in 2021, CDC updated STI guidelines for the treatment of chlamydia to overcome resistance development. According to these updated guidelines, the recommended treatment of chlamydia is now doxycycline 100 mg twice daily orally for 7 days. Alternative regimens include either azithromycin 1 g orally in a single dose or levofloxacin 500 mg once daily for 7 days. Notably, there is a delayed-release (DR) formulation of doxycycline available on the market to lighten the pill burden for patients and ease gastrointestinal effects.

Chlamydia Emerging Drugs

EVO100 (previously known as Amphora Gel) is an investigational vaginal gel to prevent urogenital chlamydia and gonorrhea in women. The drug is designed to reduce certain vaginal infections by balancing vaginal pH, thereby maintaining healthy vaginal flora and creating an environment that is detrimental to the growth and proliferation of harmful bacteria, using a different mechanism of action that may help to address drug resistance concerns
US FDA has granted the drug fast track designation for the prevention of chlamydia in women. The Phase IIb AMPREVENCE study evaluating EVO100 for the prevention of chlamydia and gonorrhea met its primary and secondary endpoints, and the study showed that EVO100 was generally safe and well-tolerated. The drug is currently being evaluated in pivotal Phase III urogenital chlamydia trachomatis and Neisseria gonorrhea infection in women. Top-line results are expected in 2022.

Chlamydia Market Outlook

The Chlamydia market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Chlamydia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Chlamydia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, the Chlamydia market in the 7MM is expected to change in the study period 2019-2032.

Presently, unmet needs in treatment for chlamydia are significant, with around 30% of patients having chronic progressive disease, unresponsive to steroid treatment. Also, there is no clear-cut PAH-specific therapy with proven efficacy or approval for treating SAPH. Thus, there is an increased demand for disease-modifying therapies to cater to the needs of patients.

Key Findings

This section includes a glimpse of the Chlamydia market in the 7MM. The market size of chlamydia in the seven major markets was USD 59.5 million in 2021.

The United States: Market Outlook

This section provides the total Chlamydia market size and market size by therapies of Chlamydia in the United States.

The United States accounts for the highest market size of chlamydia compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

For many years, azithromycin has been considered the drug of choice for treating C. trachomatis infections.

The advent of azithromycin resistance is due to its extensive usage to treat infections. For chlamydia treatment, data obtained from azithromycin versus doxycycline studies show higher treatment failure rates with azithromycin compared to doxycycline.

According to recent CDC guidelines, the recommended treatment of chlamydia is now doxycycline 100 mg twice daily orally for 7 days.

Antimicrobial stewardship is a program that supports the proper use of antimicrobials to circumvent resistance, one of the major public health problems in the United States. The new updates have been recommended based on the concerns regarding increased rates of azithromycin resistance and ceftriaxone resistance when used at lower doses.

Alternative regimens include either azithromycin 1 g orally in a single dose or levofloxacin 500 mg once daily for 7 days. Also, Ofloxacin (but not all other quinolones) effectively treat chlamydial infections. In general, erythromycin is considered the backup drug for those who cannot take another regimen.

EU-5 Countries: Market Outlook

The total Chlamydia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.

Japan Market Outlook

The total Chlamydia market size and market size by therapies of Chlamydia in Japan are also mentioned.

Chlamydia Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019-2032. The analysis covers Chlamydia market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Chlamydia Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stage. It also analyses chlamydia’s key players involved in developing targeted therapeutics.

Major players include Evofem Biosciences, Abera Bioscience, Prokarium, Quretech Bio, Aeterna Zentaris, and others, whose key products are expected to get launched in the US market by 20XX.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, and patent details for Chlamydia emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the Chlamydia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chlamydia market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Chlamydia market using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of chlamydia, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
• Comprehensive insight is provided into the Chlamydia epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for chlamydia is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
• A detailed review of the Chlamydia market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies by understanding trends shaping and driving the global Chlamydia market

Report Highlights

• In the coming years, the Chlamydia market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Chlamydia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for chlamydia. The launch of emerging therapies will significantly impact the Chlamydia market.
• A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for chlamydia.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Chlamydia Report Insights

• Patient Population
• Therapeutic Approaches
• Chlamydia Pipeline Analysis
• Chlamydia Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Chlamydia Report Key Strengths

• 11-year Forecast
• 7MM Coverage
• Chlamydia Epidemiology Segmentation
• Key Competitors
• Highly Analyzed Market

Drugs Uptake

Chlamydia Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the market share (%) distribution, and how would it look in 2032?
• What would be the Chlamydia total market size and market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings pertaining to the market across 7MM, and which country will have the largest Chlamydia market Size during the forecast period (2019-2032)?
• At what CAGR is the Chlamydia market expected to grow in the 7MM during the forecast period (2019-2032)?
• What would be the Chlamydia market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Chlamydia market growth till 2032 and the resultant market Size in the year 2032?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and unmet needs of chlamydia?
• What is the historical patient pool of chlamydia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of chlamydia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM concerning the patient population pertaining to chlamydia?
• Out of all 7MM countries, which country would have the highest prevalence of chlamydia during the forecast period (2019-2032)?
• At what CAGR is the population expected to grow in the 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of chlamydia?
• What are the current treatment guidelines for treating chlamydia in the USA, Europe, and Japan?
• What are the chlamydia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of chlamydia?
• How many therapies are developed by each company for the treatment of chlamydia?
• How many emerging therapies are in the mid-stage and late stages of development to treat chlamydia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chlamydia therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for chlamydia and its status?
• Which key designations have been granted for the emerging therapies for chlamydia?
• What are the global historical and forecasted markets for chlamydia?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Chlamydia market
• To understand the future market competition in the Chlamydia market and an Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Chlamydia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identification of strong upcoming players in the market will help devise strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Chlamydia market.
• To understand the future market competition in the Chlamydia market.